Sollis Therapeutics closed a $50 million round to support a pivotal trial of its non-opioid pain-reliever, according to Ohio-based translator NeuroTechnology Innovations Translator.
Deerfield Management led the funding round and was joined by NIT collaborators, including Medtronic (NYSE:MDT), Cardinal Health and Ohio State University.
Get the full story at our sister site, Drug Delivery Business News.
The post Sollis lands $50m for long-acting pain-relief drug appeared first on MassDevice.